Core Viewpoint - The recent IPOs in the Hong Kong stock market have shown strong profitability, with significant price increases for newly listed stocks like 恒瑞医药 (Hengrui Medicine) and MIRXES-B during the dark pool trading period [1][2]. Company Summaries 恒瑞医药 (Hengrui Medicine) - 恒瑞医药, an established A-share company listed since 2000, has a strong focus on R&D, with a projected R&D expenditure of 29.4% of total revenue in 2024 [6]. - The company has returned approximately RMB 80.29 billion in cash dividends to shareholders since its A-share listing, which is 16.8 times the capital raised at that time [6]. - 恒瑞医药 has 19 marketed innovative drugs and over 90 new molecular entities in clinical or later stages of development [6]. - The total revenue for 恒瑞医药 is projected to be RMB 28 billion in 2024, with a compound annual growth rate (CAGR) of about 14% since 2014, significantly outpacing the global pharmaceutical market's CAGR of approximately 4% [6]. - The revenue contribution from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024, while the contribution from generic drugs decreased from 60.3% in 2022 to 42.0% in 2024 [7]. MIRXES-B - MIRXES-B, founded in 2014 and based in Singapore, specializes in microRNA technology for disease screening and diagnostics, particularly in cancer detection [7]. - The company is one of the few globally to have received regulatory approval for molecular cancer screening IVD products, and is the first to receive such approval for molecular gastric cancer screening [7]. - Despite its innovative offerings, MIRXES-B is currently operating at a loss, with losses increasing from USD 0.56 million in 2022 to USD 0.696 million in 2023, and projected losses of USD 0.92 million in 2024 [7]. - The subscription multiple for MIRXES-B is significantly lower than that of 恒瑞医药, with 25 times compared to 恒瑞医药's 409 times [7]. Market Trends - The recent trend in the Hong Kong IPO market shows a strong upward movement, with only 6 out of 23 newly listed companies this year experiencing a decline on their first trading day, while others have seen substantial gains [8].

近期，港股IPO的赚钱效应太强了！ 目前，恒瑞医药拥有19款已上市的新分子实体创新药和逾90款处于临床或更后期阶段的新分子实体在研创新药。 恒瑞医药2024年的总收入为人民币280亿元，自2014年起的复合年增长率约为14%，远超同期全球制药市场约4%的复合年增长率。此外，创新药已成为公司收入的 一项主要来源。创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。公司的仿制药销售收入占总收入的百分比 由2022年的60.3%减至2023年的53.4%，并进一步减至2024年的42.0%。 而MIRXES-B则是一家成立于2014年，总部位于新加坡的微小核糖核酸（miRNA）技术公司，致力于使疾病筛查诊断解决方案在亚洲关键市场（包括新加坡及中 国）触手可及。 根据弗若斯特沙利文的资料，MIRXES-B是用于癌症及其他疾病早期检测的、有效的、无创的、可负担的、基于血液的miRNA检测试剂盒的提供商。MIRXES-B是 全球为数不多的已获得分子癌症筛查行业*IVD产品监管批准的公司之一，同时MIRXES-B也是全球范围内首家且唯一一家获得分子胃癌筛查I ...

Group 1 - The core viewpoint of the article highlights a surge in H-share listings by leading A-share companies, with significant capital inflow into the Hong Kong market, driven by international investors' re-evaluation of Chinese assets [1][2] - The recent IPO boom in Hong Kong has raised a total of HKD 145 billion in the past year, marking a 2.7 times increase year-on-year, with major contributions from companies like Ningde Times and Midea Group [2] - The previous IPO wave in Hong Kong, initiated by Alibaba's return in November 2019, lasted nearly three years, indicating a cyclical trend in capital movements and market sentiment [1][2] Group 2 - The top ten IPOs in Hong Kong predominantly come from mainland China, contributing 75% of the total fundraising, showcasing the dominance of A-share companies in the Hong Kong market [2] - The Hong Kong Stock Exchange experienced over HKD 1 trillion in IPO financing from 2019 to 2021, with 2019 being the peak year with 183 IPOs raising HKD 312.7 billion [2] - The recent market rally in Hong Kong, with an increase of nearly 5000 points since April 9, suggests a positive outlook for the medium to long term, driven by continued capital inflow and the entry of more quality companies [1]

Group 1 - Heng Rui Pharmaceutical has set the final price for its H-share issuance at HKD 44.05 per share, which is the upper limit of the previously expected price range [1] - The H-shares will officially be listed on the Hong Kong Stock Exchange on May 23, with cornerstone investors including GIC, Invesco, UBS Global Asset Management, Hillhouse Capital, and Boyu Capital [1] - The purpose of this H-share issuance is to further promote the company's global strategic layout, enhance its international brand image, and strengthen connections with overseas capital markets [1] Group 2 - Chao Hong Ji is planning to issue H-shares for listing on the Hong Kong Stock Exchange, with details and plans yet to be finalized [2] - The company has experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days [2] - This move is aimed at expanding the international market and enhancing brand influence, which is expected to positively impact the company's long-term development [2] Group 3 - ZTO Express reported a revenue of CNY 10.892 billion for Q1 2025, representing a year-on-year increase of 9.4% [3] - The gross profit for the same period was CNY 2.689 billion, a decrease of 10.4% year-on-year, while the adjusted net profit was CNY 2.259 billion, up 1.6% year-on-year [3] - The company completed a total of 8.5 billion packages in Q1, marking a year-on-year growth of 19.1% [3] Group 4 - Hangpin Life Technology announced the acquisition of 1 million shares of China Petroleum at an average price of HKD 6.285 per share, totaling HKD 6.285 million [4] - This acquisition is part of the company's diversification strategy, aimed at increasing investment returns and financial flexibility [4] - The shares acquired will be held as a long-term investment to achieve capital appreciation and potential dividend income [4]

Group 1: IPO Market Overview - The Hong Kong stock market is experiencing a new wave of IPO activity, with total fundraising reaching HKD 145 billion in the past year, a year-on-year increase of 2.7 times [1][2] - The top ten IPOs, primarily from mainland companies, contributed 75% of the total fundraising, with notable leaders being CATL and Midea Group [2][3] - As of May 21, 2025, 76 new stocks have been listed, with 23 companies going public this year alone, raising a total of HKD 653 billion [2] Group 2: Key Players and Fundraising - CATL and Midea Group led the fundraising efforts with HKD 410 billion and HKD 356.66 billion respectively, marking them as the top fundraisers for 2024 and 2025 [2][4] - Other significant players in the second tier include Horizon Robotics, SF Express, and China Resources Beverage, each raising over HKD 50 billion [2][4] - The third tier consists of consumer-related companies like Mixue Group and Chifeng Gold, raising between HKD 20 billion and HKD 40 billion [3][4] Group 3: Globalization and Strategic Moves - Chinese companies are accelerating their global expansion through the "A+H" dual capital market strategy, which is crucial for their international growth [5][6] - Leading companies in various sectors, including pharmaceuticals and consumer electronics, are planning to list in Hong Kong to enhance their global presence [6][7] - The automotive sector is also seeing increased activity, with companies like Seres and Chery Motors planning to raise funds through IPOs in Hong Kong [8] Group 4: Capital Inflows and Market Dynamics - The weakening US dollar has led to increased capital inflows into the Hong Kong market, as investors seek to buy Chinese assets [9][10] - The Hong Kong Monetary Authority has injected over HKD 1.16 billion into the market to support the Hong Kong dollar, reflecting strong demand for stocks [9] - The successful IPOs of companies like CATL have created a "money-making effect," encouraging more mainland companies to pursue listings in Hong Kong [10] Group 5: Regulatory Environment - The Hong Kong regulatory framework is evolving to facilitate the listing process for mainland companies, including the introduction of a "special line" for tech and biotech firms [11][12] - Recent changes have lowered the minimum requirements for H-share listings, making it easier for companies to access the Hong Kong capital market [12]

Investment Rating - The report assigns an IPO-specific rating of 6.1, based on various criteria including company operations, industry outlook, valuation, and market sentiment [6][8]. Core Insights - The company, Heng Rui Pharmaceutical, is a leading innovative pharmaceutical enterprise rooted in China, with projected revenues of 27.985 billion RMB (+22.6%) and a net profit of 6.337 billion RMB (+47.3%) for 2024. The gross margin is expected to improve by 1.6 percentage points to 86.2% [1]. - The core growth driver is the revenue from innovative drugs, which is expected to increase from 38.1% of total revenue in 2022 to 46.3% in 2024, supported by key products like PD-L1&TGF-β and HER2ADC [1]. - The global pharmaceutical market is projected to grow from $1,472.3 billion in 2023 to $1,938.7 billion by 2028, with a CAGR of 5.7%. The Chinese pharmaceutical market is expected to grow from 1,618.3 billion RMB in 2023 to 2,342.0 billion RMB by 2028, with a CAGR of 7.7% [2]. - The company has a strong R&D capability, with an investment of 8.2 billion RMB in 2024, representing 29.4% of total revenue, and cumulative R&D investment exceeding 44 billion RMB [3]. - The company has a robust commercialization capability with a sales and marketing team of approximately 9,000, covering over 22,000 hospitals and 200,000 retail pharmacies in China [4]. Company Overview - Heng Rui Pharmaceutical is positioned as a global leader in innovative pharmaceuticals, focusing on unmet medical needs across various therapeutic areas, including oncology, metabolic and cardiovascular diseases, immunology, and neuroscience [3]. - The company has over 110 commercialized drugs, including 19 new molecular entities and four other innovative drugs [3]. - The financial health of the company is strong, with a debt-to-asset ratio of 8% and no interest-bearing debt, allowing for sustainable R&D investments [4].